Reduction of the closure time of postoperative enterocutaneous fistulas with fibrin sealant.

AIM: To assess whether the use of fibrin sealant shortens the closure time of postoperative enterocutaneous fistulas (ECFs). METHODS: The prospective case-control study included 70 patients with postoperative ECFs with an output of < 500 mL/d, a fistulous tract of > 2 cm and without any local complication. They were divided into study (n = 23) and control groups (n = 47). Esophageal, gastric and colocutaneous fistulas were monitored under endoscopic visualization, which also allowed fibrin glue application directly through the external hole. Outcome variables included closure time, time to resume oral feeding and morbidity related to nutritional support. RESULTS: There were no differences in mean age, fistula output, and follow-up. Closure-time for all patients of the study group was 12.5 +/- 14.2 d and 32.5 +/- 17.9 d for the control group (P < 0.001), and morbidity related to nutritional support was 8.6% and 42.5%, respectively (P < 0.01). In patients with colonic fistulas, complete closure occurred 23.5 +/- 19.5 d after the first application of fibrin glue, and spontaneous closure was observed after 36.2 +/- 22.8 d in the control group (P = 0.36). Recurrences were observed in 2 patients because of residual disease. One patient of each group died during follow-up as a consequence of septic complications related to parenteral nutrition. CONCLUSION: Closure time was significantly reduced with the use of fibrin sealant, and oral feeding was resumed faster. We suggest the use of fibrin sealant for the management of stable enterocutaneous fistulas.

[Comparison of sublingual ketorolac vs. IV metamizole in the management of pain after same-day surgery]. / Comparación de ketorolaco sublingual contra metamizol endovenoso en el manejo del dolor posoperatorio en cirugía de corta estancia.

BACKGROUND: Therapeutic pain is one of the most important outcome measures in surgery. Comparative studies investigating ketorolac efficiency in ambulatory surgery have generally been restricted to IV administration. We compared analgesic effectiveness of sublingual ketorolac and metamizole in short stay surgery. METHODS: This was a randomized single-blind clinical trial. All patients received either a three-dose (30 mg) of sublingual ketorolac or 1 g of IV metamizole, respectively. We evaluated pain with a visual/analog scale (VAS). Side effects were also recorded. Statistical analysis included t-test or Mann-Whitney U test and Fisher exact test or chi(2). Absolute risk reduction (ARR), odds ratio (OR), confidence interval (CI), relative risk ratio (RRR) and numbers needed to treat (NNT) were also evaluated. RESULTS: Rescue doses of analgesics were greater in patients receiving metamizole although the difference was not significant (p = 0.286). Mean VAS score was lower in the ketorolac group at 8 h after surgery, with no statistical difference (p = 0.06). ARR for severe pain score was almost 5% (OR = 1.78). Adverse effects did not show differences between groups (p = 0.642). CONCLUSIONS: Ketorolac and metamizole have comparable effects and can be safely used in ambulatory settings.

Comparación de ketorolaco sublingual contra metamizol endovenoso en el manejo del dolor posoperatorio en cirugía de corta estancia / Comparison of sublingual ketorolac vs. IV metamizole in the management of pain after same-day surgery

Introducción: El dolor posquirúrgico es uno de los retos más importantes en cirugía, los estudios comparativos con ketorolaco en pacientes con cirugía de corta estancia se han restringido generalmente a la administración intravenosa. Por lo tanto, comparamos la eficacia analgésica de ketorolaco sublingual y metamizol en cirugía de corta estancia. Material y métodos: Ensayo clínico controlado ciego simple; los pacientes recibieron 30 mg de ketorolaco sublingual o 1 g de metamizol endovenoso, cada ocho horas, durante las primeras 24 horas posoperatorio. Se evaluó dolor con la escala análoga visual (EVA). También fueron evaluados los efectos colaterales. Para el análisis estadístico se utilizó t de dos colas o U de Mann-Whitney y la prueba exacta de Fisher o χ2, además del cálculo de reducción de riesgo absoluto, razón de momios (OR), intervalo de confianza a 95 %, reducción del riesgo relativo y número necesario a tratar. Resultados: El consumo de analgésico suplementario fue mayor en el grupo de metamizol pero sin diferencia significativa (p = 0.286). Durante el estudio, la EVA promedio fue menor para ketorolaco que para metamizol, sobre todo a las ocho horas de posoperatorio, pero sin diferencia estadística (p = 0.06). La reducción del riesgo absoluto para cuadros de dolor severo fue de casi 5 % (OR = 1.78). No hubo diferencia en la presentación de efectos adversos (p = 0.642). Conclusiones: Tanto ketorolaco como metamizol demostraron un efecto comparable y pueden ser utilizados con seguridad.

BACKGROUND: Therapeutic pain is one of the most important outcome measures in surgery. Comparative studies investigating ketorolac efficiency in ambulatory surgery have generally been restricted to IV administration. We compared analgesic effectiveness of sublingual ketorolac and metamizole in short stay surgery. METHODS: This was a randomized single-blind clinical trial. All patients received either a three-dose (30 mg) of sublingual ketorolac or 1 g of IV metamizole, respectively. We evaluated pain with a visual/analog scale (VAS). Side effects were also recorded. Statistical analysis included t-test or Mann-Whitney U test and Fisher exact test or chi(2). Absolute risk reduction (ARR), odds ratio (OR), confidence interval (CI), relative risk ratio (RRR) and numbers needed to treat (NNT) were also evaluated. RESULTS: Rescue doses of analgesics were greater in patients receiving metamizole although the difference was not significant (p = 0.286). Mean VAS score was lower in the ketorolac group at 8 h after surgery, with no statistical difference (p = 0.06). ARR for severe pain score was almost 5% (OR = 1.78). Adverse effects did not show differences between groups (p = 0.642). CONCLUSIONS: Ketorolac and metamizole have comparable effects and can be safely used in ambulatory settings.

[Duodenal diverticulum in the third portion of duodenum as a cause of upper gastrointestinal bleeding and chronic abdominal pain. Case report and literature review]. / Divertículo duodenal en la tercera porción del duodeno como causa de sangrado del tubo digestivo alto y dolor crónico abdominal. Informe de un caso y revisión de la literatura.

BACKGROUND: Duodenal diverticulum is a little-known pathology. The duodenum represents second place in frequency for the presence of diverticula in the digestive tract after the colon. Duodenal diverticulum as a cause of hemorrhage of the upper gastrointestinal (GI) tract has been described as an infrequent complication, although it must be considered in patients with digestive hemorrhage without evident cause at the esophagogastric level. Localization of diverticula in the third or fourth portions of the duodenum is rare and the diverticula are asymptomatic in 90% of cases. Diagnosis is made by endoscopy, contrast X-rays of the upper GI tract, selective arteriography and as a transoperative finding. The objective of this study was to identify and analyze the clinical presentation of duodenal diverticulum to familiarize surgeons and gastroenterologists when there is suspicion of the diagnosis. CLINICAL CASE: We report the case of an 85-year-old female presenting with massive upper GI tract hemorrhage and chronic abdominal pain due to a duodenal diverticulum located in the third portion of the duodenum. Diagnosis was made with upper GI barium series because visualization of the diverticulum was not possible by endoscopy. Other therapeutic options are described in the literature. A successful simple diverticulectomy, manually opened with a two-plane transversal incision, was performed on the patient. After >12 months of follow-up, the patient is completely asymptomatic. DISCUSSION: Clinical diagnosis presents difficulty because a classic presentation does not exist. Symptoms are generally vague, <10% of the duodenal diverticulum are frankly symptomatic, and <1 to 2% will require surgical resolution. CONCLUSIONS: Hemorrhage of the upper GI tract and chronic abdominal pain secondary to duodenal diverticulum present with recurrence and may be associated with the presence of duodenal diverticulum when other sources of bleeding are not found.

Divertículo duodenal en la tercera porción del duodeno como causa de sangrado del tubo digestivo alto y dolor crónico abdominal: informe de un caso y revisión de la literatura / Duodenal diverticulum in the third portion of duodenum as a cause of upper gastrointestinal bleeding and chronic abdominal pain: case report and literature review

BACKGROUND: Duodenal diverticulum is a little-known pathology. The duodenum represents second place in frequency for the presence of diverticula in the digestive tract after the colon. Duodenal diverticulum as a cause of hemorrhage of the upper gastrointestinal (GI) tract has been described as an infrequent complication, although it must be considered in patients with digestive hemorrhage without evident cause at the esophagogastric level. Localization of diverticula in the third or fourth portions of the duodenum is rare and the diverticula are asymptomatic in 90% of cases. Diagnosis is made by endoscopy, contrast X-rays of the upper GI tract, selective arteriography and as a transoperative finding. The objective of this study was to identify and analyze the clinical presentation of duodenal diverticulum to familiarize surgeons and gastroenterologists when there is suspicion of the diagnosis. CLINICAL CASE: We report the case of an 85-year-old female presenting with massive upper GI tract hemorrhage and chronic abdominal pain due to a duodenal diverticulum located in the third portion of the duodenum. Diagnosis was made with upper GI barium series because visualization of the diverticulum was not possible by endoscopy. Other therapeutic options are described in the literature. A successful simple diverticulectomy, manually opened with a two-plane transversal incision, was performed on the patient. After >12 months of follow-up, the patient is completely asymptomatic. DISCUSSION: Clinical diagnosis presents difficulty because a classic presentation does not exist. Symptoms are generally vague, <10% of the duodenal diverticulum are frankly symptomatic, and <1 to 2% will require surgical resolution. CONCLUSIONS: Hemorrhage of the upper GI tract and chronic abdominal pain secondary to duodenal diverticulum present with recurrence and may be associated with the presence of duodenal diverticulum when other sources of bleeding are not found.

[Cervical esophagogastrostomy dehiscence after gastric pull-up for type I esophageal atresia. Case report of a patient successfully treated with fibrin glue and a review of the literature]. / Dehiscencia de esófago-gastroanastomosis cervical posterior a ascenso gástrico por atresia esofágica tipo I. Reporte de un caso exitoso tratado con gel de fibrina y revisión de literatura.

INTRODUCTION: The treatment of choice for type 1 esophageal atresia is surgery to re-establish continuity of gastrointestinal tract by colon interposition or gastric pull-up. Incidence of cervical anastomosis dehiscence is 20-40%. Although it is not a serious complication, it requires a fasting period and nutritional support to achieve spontaneous closure within 2-4 weeks. AIM: To report successful treatment of cervical esophageal-gastric anastomosis dehiscence after gastric transposition using fibrin glue. CASE PRESENTATION: A 17-month-old female child, the product of a first pregnancy, was delivered by caesarean section at 35 weeks gestation in response to fetal distress; the child weighed 1,800 g at birth and had APGAR score of 6-8. At 7 h of extra-uterine life, she was diagnosed with type I esophageal atresia and cervical esophagostomy was performed. Stamm-type gastrostomy was used for enteral nutrition until she was 17 months of age. With a weight of 9 kg, the child underwent esophageal substitution with transhiatal gastric transposition, cervical anastomosis, and jejunostomy. On the seventh day postsurgery, surgical wound infection was observed, producing purulent material and saliva (45 ml in 24 h). On the 10th day, esophagogram was performed that revealed 30% anastomosis dehiscence and 2-cm fistulous tract with no abscess. On the 11th day, 3 ml of fibrinogen (80 mg/mL) activated with thrombin (1,000 uL/mL), both of human extraction (Quixil, Omrix, Tel Aviv, Israel) was applied through fistula tract. RESULT: The following day, the patient presented with cough access, expelling the fibrin glue plug. A similar dose was given that achieved a null output volume during the following 24 h. Subsequently, she began oral feeding with liquids, incorporating a normal diet over the following 2 months. At present, she is 3 years 2 months of age, weighs 15 kg, and is able to eat any kind of food without dysphagia. CONCLUSIONS: We demonstrated that use of biological adhesives can shorten time required to achieve closure of high- and low-output volume fistulas. In the present case, use of fibrin glue to obliterate the fistulous tract gave satisfactory results, reducing time to spontaneous closure and facilitating early commencement of oral feeding. Cases of enterocutaneous fistula closure reviewed in the literatura generally involve adults, but the technique can be used in children with this type of complication.

Operación de Hartmann: experiencia institucional de 92 casos consecutivos / Hartmann's procedure: institutional experience of 92 consecutive cases

Antecedentes: desde su descripción en 1923, el procedimiento de Hartmann es ampliamente utilizado en el tratamiento quirúrgico de complicaciones agudas del colon izquierdo, cuando no es posible realizar lavado mecánico preoperatorio y/o cuando Objetivo: analizar los resultados de la operación de Hartmann en el tratamiento quirúrgico de pacientes consecutivos en una misma institución, durante un intervalo de 30 meses.existe alta posibilidad de dehiscencia anastomótica.Tipo de estudio: prospectivo, no al azar y longitudinal.Material y métodos: pacientes tratados mediante procedimiento de Hartmann entre marzo de 1995 y septiembre de 1998. Se realizó análisis de indicación del procedimiento, hallazgos transoperatorios, morbilidad y mortalidad, así como la frecuencia de reversión con reinstalación de la continuidad intestinal y su morbimortalidad.Resultados: se sometieron al procedimiento de Hartmann 92 pacientes. La edad promedio de los pacientes fue de 60 + 25 años (margen de 21 a 88 años) y 60 por ciento superaba los 65 años de edad. El procedimiento fue de urgencia en 91 por ciento de los casos. Los pacientes presentaban en su mayoría sepsis intraabdominal (56 por ciento) y patología colónica benigna (83 por ciento). Se detectó morbilidad de 34 por ciento y mortalidad de 19 por ciento. Durante el seguimiento se restauró la continuidad intestinal en 32 por ciento de los casos sin ocurrir fatalidades.Conclusiones: el procedimiento de Hartmann es buena opción para el tratamiento quirúrgico no electivo de patología rectosigmoidea complicada. La morbilidad y la mortalidad de la operación depende en gran medida del grado de sepsis preoperatoria y de la condición preexiste del paciente. La baja tasa de restauración en la continuidad intestinal probablemente se debe a un corto tiempo de seguimiento

Complicaciones abdominales consecutivas a derivación cardiopulmonar / Abdominal complications resulting from cardiopulmonary derivation

Objetivo. Conocer la frecuencia de complicaciones intraabdominales y su impacto en la supervivencia de pacientes sujetos a DCP para procedimientos quirúrgicos comunes a corazón abierto. Antecedentes. Las complicaciones gastrointestinales después de cirugía cardiaca con derivación cardiopulmonar, tienen incidencia del 0.3 al 3 por ciento, pero la mortalidad puede sobrepasar 60 por ciento. Pese a las mejorías en el cuidado pre, trans, y posoperatorio, la impresión general ha sido que las complicaciones abdominales permanecen como un problema significativo. Tipo de Estudio. Retrospectivo de casos y controles. Material y métodos. Pacientes consecutivos sometidos a cirugía cardiaca con derivación cardiopulmonar, entre marzo de 1995 y marzo de 1997. Se identificó cualquier complicación abdominal, su diagnóstico, manejo médico o quirúrgico y mortalidad. Resultados. Se estudiaron 1,352 pacientes de los cuales 516 fueron operados por revascularización coronaria (38 por ciento), 502 (37 por ciento) por reemplazo valvular, 68 (5.2 por ciento) una combinación de reemplazo valvular y revascularización, 144 (10.6 por ciento) corrección de defectos congénitos, y 122 (9.6 por ciento) tratados por padecimientos diversos. Desarrollaron complicaciones 44 pacientes (3.3 por ciento) y éstas fueron íleo intestinal posoperatorio en 14 casos (32 por ciento), la mitad de ellos tuvo hiperamilasemia. Las complicaciones hepatobiliares representaron 29.5 por ciento (13 casos). Diez pacientes (22.7 por ciento) tuvieron enfermedad ulceropéptica complicada con hemorragia o perforación. La pandreatitis aguda grave se observó en 4.5 por ciento de los casos al igual en dos pacientes con necrosis intestinal. Tres casos presentaron complicaciones quirúrgicas no relacionadas con DCP y fueron traumatismo hepático grado I, apendicitis aguda y colitis amibiana. La mortalidad fue de 11/44 (25 por ciento). Como grupo control, se analizaron 73 pacientes operados el día o alrededor de los días como los del grupo de estudio y que no desarrollaron complicaciones gastrointestinales. La mortalidad en este grupo fue de 5/73 (6.8 por ciento). ...